IMpella-Protected cArdiaC Surgery Trial (IMPACT)

Not Applicable

• Conditions: Left Ventricular Dysfunction
• Interventions: Device: Impella 5.5 with SmartAssist

• Registration Number: NCT05529654
• Lead Sponsor: Abiomed Inc.

Brief Summary

The purpose of this Trial is to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients, with the overall aim to evaluate if using Impella 5.5 with SmartAssist (Impella 5.5) peri-operatively improves early hemodynamics, end-organ function and clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.

Detailed Description

This is a prospective single-armed Trial to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients. A concurrent Registry will also be performed to collect information on patients meeting Exclusion Criteria and those not approached for enrollment. The overall aim is to evaluate if using Impella 5.5 peri-operatively improves early hemodynamics, end-organ function and subsequent clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.

Study Timeline

• Study First Submitted: 2022-08-24
• Study First Submitted QC: 2022-09-02
• Study First Posted: 2022-09-07
• Study Start: 2023-09-21
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-04
• Last Update Posted: 2025-05-07
• Primary Completion: 2026-01-31
• Study Completion: 2026-01-31

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Hemodynamically stable patients undergoing one of the following cardiac surgery procedures on CPB including aortic cross-clamping and cardioplegic arrest:

   • Isolated CABG

   • Isolated mitral valve repair or mitral valve replacement (MVR)

   • Isolated biological aortic valve replacement (AVR)

   • At least two of the following: CABG, MVR, AVR, or tricuspid valve repair or replacement (TVR)

   • Additional concomitant procedures permitted:

     1. Atrial septal defect (ASD) or patent foramen ovale (PFO) repair or closure
     2. Atrial fibrillation ablation procedures
     3. Left atrial ablation (all forms including complete left/right side Cox Maze)
     4. Coronary endarterectomy

2. LVEF within 30 days before surgery of either:

   • ≤25% measured by echocardiogram or cardiac MRI, OR

   • LVEF ≤35%, measured as above, for patients with significant mitral regurgitation (MR 3+ or 4+) and planned corrective mitral valve surgery (including MV replacement or repair)

     • Any subject with EF <20% must have viability assessment performed to assess CABG candidacy (MRI preferred)

3. Age 18 years or older

4. Subject (or subject's LAR, if allowed by IRB) has signed Informed Consent Form

Exclusion Criteria

1. Salvage operation (cardiac arrest within 24 hours prior to index surgery)
2. Unresponsive state within 24 hours of the time of surgery
3. Any inotrope within 72 hours of surgery
4. Any MCS device (such as IABP, ECMO, Impella®, CentriMag™ or TandemHeart®) in place at time of informed consent and less than 24 hours prior to index study procedure
5. RV dysfunction requiring mechanical or inotropic support pre-operatively and/or likely to be needed post-operatively
6. Index procedures requiring total circulatory arrest (TCA), such as aortic arch replacement, planned durable LVAD, durable RVAD, planned right-sided temporary mechanical support of any kind, total artificial heart (TAH), cardiac transplantation, pericardiectomy, pulmonary thromboendarterectomy and septal myectomy
7. Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade or other conditions in which cardiac output is dependent on venous return
8. Ventricular septal defect (VSD)
9. Stroke within 30 days of the index cardiac surgical procedure
10. Prior mantle field chest irradiation
11. Prior solid organ or hematologic transplantation (heart, kidney, liver, lung, pancreas, bone marrow) or durable LVAD
12. History of chronic dialysis
13. Pre-existing liver dysfunction defined as: Child-Pugh Class B or C
14. Pre-existing pulmonary disease requiring home oxygen or "severe pulmonary disease" determined by enrolling Investigator
15. Systemic active infection or evidence of systemic bacterial, fungal or viral infection within 72 hours before surgery (blood culture positive with leukocytosis)
16. Confirmed COVID-19 infection within two weeks prior to operation
17. Suspected or known pregnancy
18. Participation in the active treatment or follow-up phase of another interventional clinical trial of an investigational drug or device which has not reached its primary endpoint
19. Known contraindication to heparin; History of bleeding diathesis or known coagulopathy or will refuse blood transfusions
20. Inability to perform aortic cross-clamp, such as due to porcelain aorta
21. Any contraindication or inability to place Impella 5.5 (per the IFU), including LV thrombus and/or presence of a mechanical aortic valve
22. Any organ condition, concomitant disease (e.g., psychiatric illness, current severe alcoholism or current drug abuse, cancer, hepatic or kidney disease), with life expectancy of ≤2 years or other abnormality that itself or the treatment of which could interfere with the conduct of the trial or that, in the opinion of the investigator and/or Sponsor's medical monitor, would pose an unacceptable risk to the patient in the trial.
23. Patient has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with trial procedures
24. Patient belongs to a vulnerable population [Vulnerable patient populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention]

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Impella Arm	Impella 5.5 with SmartAssist	Impella 5.5 with SmartAssist

Primary Outcome Measures

Name	Time	Method
Composite of All-Cause Mortality	90 days
Stroke (as defined by STS)	90 days
New requirement for Renal Replacement Therapy (RRT)	90 days
Rate of Post-Cardiotomy Cardiac Failure	Hospital discharge, usually within 30 days	The rate of post-cardiotomy cardiac failure evaluated at hospital discharge.

Secondary Outcome Measures

Name	Time	Method
Number of attempts to wean from CPB	Intra-op, usually within 1 day
Duration of mechanical ventilation	ICU discharge, usually within 30 days
Duration and dosages of inotropes and vasopressors. Duration of mechanical circulatory support (Hours)	ICU Discharge, usually within 30 days	measured in number of hours of dosage
Acute Kidney Injury	within 7 days or at ICU Discharge (usually within 30 days)	a modified KDIGO Stages 2-3
Vasoactive-inotropic score (VIS)	ICU Discharge, usually within 30 days
Cardiovascular mortality	Hospital discharge, usually within 30 days
Major Hemolysis	Hospital Discharge, usually within 30 days	defined by MCS-ARC
Major Vascular Complications	Hospital Discharge, usually within 30 days	defined by MCS-ARC
Major Bleeding	Hospital Discharge, usually within 30 days	defined by STS
Length of ICU Stay	ICU Discharge, usually within 30 days
Length of Hospital Stay	Hospital Discharge, usually within 30 days
Quality of Life (QoL) assessed by KCCQ	90 Days Post-Op
Physical Activity	90 Days Post-Op	Measured by (Katz Activities of Daily Living (ADL) and Lawton Instrumental ADL (IADL)
Technical Success	Intra-op, usually within 1 day	The successful use of the Impella 5.5 device will be assessed by the proportion of patients who undergo successful Impella implant, as well as the proportion of patients demonstrating successful wean off CPB.

Trial Locations

Locations (23)

Tri-City Medical Center; 🇺🇸 San Diego, California, United States

University of Florida; 🇺🇸 Gainesville, Florida, United States

NCH Rooney Heart Institute; 🇺🇸 Naples, Florida, United States

Minneapolis Heart Institute Foundation/Abbott Northwestern Hospital; 🇺🇸 Minneapolis, Minnesota, United States

Cardiology Associates Research Group; 🇺🇸 Jonesboro, Arkansas, United States

Keck School of Medicine; 🇺🇸 Los Angeles, California, United States

University of Colorado; 🇺🇸 Aurora, Colorado, United States

Emory University Hospital; 🇺🇸 Atlanta, Georgia, United States

Mass General Hospital; 🇺🇸 Boston, Massachusetts, United States

Brigham & Women's; 🇺🇸 Boston, Massachusetts, United States

SSM Health Saint Louis University Hospital; 🇺🇸 Saint Louis, Missouri, United States

Barnes-Jewish Hospital; 🇺🇸 Saint Louis, Missouri, United States

Hackensack University Medical Center; 🇺🇸 Hackensack, New Jersey, United States

Montefiore Medical Center; 🇺🇸 Bronx, New York, United States

NYU Langone Health; 🇺🇸 New York, New York, United States

New York- Presbyterian Hospital/ Columbia University Medical Center; 🇺🇸 New York, New York, United States

New Hanover Regional Medical Center; 🇺🇸 Wilmington, North Carolina, United States

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States

Providence St. Vincent Medical Center; 🇺🇸 Portland, Oregon, United States

Hospital of The University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Centennial Heart Cardiovascular; 🇺🇸 Nashville, Tennessee, United States

University of Texas Austin Dell Medical School/Ascension Texas; 🇺🇸 Austin, Texas, United States

Baylor Scott and White - Plano; 🇺🇸 Plano, Texas, United States